Category:Antiparasitics: Difference between revisions
Category page
More actions
Create canonical category-page article (history-first) |
Rewrite per canonical category-page spec (history-first article) |
||
| Line 9: | Line 9: | ||
The ectoparasitic medicines are a smaller sub-category. [[wikipedia:Permethrin|Permethrin]] (a synthetic pyrethroid) is the standard topical agent for scabies and head lice. The ivermectin oral and topical formulations are used for scabies and for rosacea (off-label, on the demodex-mite hypothesis of rosacea). The newer spinosad and abametapir topical preparations have been added for head lice resistant to permethrin and malathion. | The ectoparasitic medicines are a smaller sub-category. [[wikipedia:Permethrin|Permethrin]] (a synthetic pyrethroid) is the standard topical agent for scabies and head lice. The ivermectin oral and topical formulations are used for scabies and for rosacea (off-label, on the demodex-mite hypothesis of rosacea). The newer spinosad and abametapir topical preparations have been added for head lice resistant to permethrin and malathion. | ||
The contemporary clinical pharmacology of the antiparasitics is dominated by access and resistance issues. Many of the parasitic diseases are concentrated in low-income tropical settings, and the development and pricing of antiparasitic medicines have historically been driven less by commercial return than by donation programmes, by [[wikipedia:Drugs for Neglected Diseases initiative|public-private partnerships]] (DNDi, the [[wikipedia:Medicines for Malaria Venture|Medicines for Malaria Venture]]), and by World Health Organization elimination targets. Artemisinin partial resistance has emerged in southeast Asia and is spreading to Africa, threatening the gains of the last twenty years. The eradication of dracunculiasis (guinea worm) is nearing completion through a combination of water filtration and case management rather than through a medicine; the elimination of onchocerciasis and lymphatic filariasis, by contrast, depends on continued ivermectin and albendazole mass | The contemporary clinical pharmacology of the antiparasitics is dominated by access and resistance issues. Many of the parasitic diseases are concentrated in low-income tropical settings, and the development and pricing of antiparasitic medicines have historically been driven less by commercial return than by donation programmes, by [[wikipedia:Drugs for Neglected Diseases initiative|public-private partnerships]] (DNDi, the [[wikipedia:Medicines for Malaria Venture|Medicines for Malaria Venture]]), and by World Health Organization elimination targets. Artemisinin partial resistance has emerged in southeast Asia and is spreading to Africa, threatening the gains of the last twenty years. The eradication of dracunculiasis (guinea worm) is nearing completion through a combination of water filtration and case management rather than through a medicine; the elimination of onchocerciasis and lymphatic filariasis, by contrast, depends on continued ivermectin and albendazole mass administration programmes. | ||
== Subcategories indexed == | == Subcategories indexed == | ||